There is a chance that the activities of MSD, the former Organon, the Netherlands will be continued by a new Dutch pharmaceutical company.
The risk is real that a substantial part of the research herein can be accommodated. RTL Z reports that according to reports in the New York Times.
It would involve the division Women’s Health and hormones. Because the parent company Merck & Co. Inc. (MRK) decided last summer not to invest in longer, are the key research areas and products available for partnering. This Ton Rijnders, founder and until early this month, head of R & D of Organon, to the business newspaper said.